| Dr Amanda Perri Selwyn Barker, MD | |
|
10800 Magnolia Ave, Riverside, CA 92505-3043 | |
| (951) 898-7460 | |
| Not Available |
| Full Name | Dr Amanda Perri Selwyn Barker |
|---|---|
| Gender | Female |
| Speciality | Pain Management |
| Experience | 20 Years |
| Location | 10800 Magnolia Ave, Riverside, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306965942 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2081P2900X | Physical Medicine & Rehabilitation - Pain Medicine | A107071 (California) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Southern California Permanente Medical Group | 6002729175 | 7951 |
News Archive
The Prevent COVID U study, which launched in late March 2021 to evaluate SARS-CoV-2 infection and transmission among university students vaccinated with the Moderna COVID-19 Vaccine, has expanded beyond the university setting to enroll young adults ages 18 through 29 years and will now also include people in this age group who choose not to receive a vaccine.
Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that Dr. Geoffrey I. Shapiro of Dana-Farber Cancer Institute, presented preclinical and clinical data on STA-9090, a potent second-generation Hsp90 inhibitor, at IASLC (International Association for the Study of Lung Cancer) 10th Annual Targeted Therapies of the Treatment of Lung Cancer Meeting in Santa Monica, CA.
Isis Pharmaceuticals, Inc. announced the initiation of two Phase 2 studies of ISIS-EIF4ERx in patients with non-small cell lung cancer and prostate cancer. These studies are part of Isis' broad Phase 2 development program designed to evaluate ISIS-EIF4ERx in multiple types of cancer. ISIS-EIF4ERx targets eukaryotic initiation factor-4E (eIF-4E), a traditionally "undruggable" target that is thought to promote tumor growth and metastasis in many cancers.
A new study featured in the Journal of the Academy of Nutrition and Dietetics found that after drinking a small amount of caffeine, participants consumed 10 percent less at a breakfast buffet provided by researchers, but this effect did not persist throughout the day and had no impact on participants' perceptions of their appetites.
› Verified 9 days ago
| Entity Name | Southern California Permanente Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770515280 PECOS PAC ID: 6002729175 Enrollment ID: O20031110000678 |
News Archive
The Prevent COVID U study, which launched in late March 2021 to evaluate SARS-CoV-2 infection and transmission among university students vaccinated with the Moderna COVID-19 Vaccine, has expanded beyond the university setting to enroll young adults ages 18 through 29 years and will now also include people in this age group who choose not to receive a vaccine.
Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that Dr. Geoffrey I. Shapiro of Dana-Farber Cancer Institute, presented preclinical and clinical data on STA-9090, a potent second-generation Hsp90 inhibitor, at IASLC (International Association for the Study of Lung Cancer) 10th Annual Targeted Therapies of the Treatment of Lung Cancer Meeting in Santa Monica, CA.
Isis Pharmaceuticals, Inc. announced the initiation of two Phase 2 studies of ISIS-EIF4ERx in patients with non-small cell lung cancer and prostate cancer. These studies are part of Isis' broad Phase 2 development program designed to evaluate ISIS-EIF4ERx in multiple types of cancer. ISIS-EIF4ERx targets eukaryotic initiation factor-4E (eIF-4E), a traditionally "undruggable" target that is thought to promote tumor growth and metastasis in many cancers.
A new study featured in the Journal of the Academy of Nutrition and Dietetics found that after drinking a small amount of caffeine, participants consumed 10 percent less at a breakfast buffet provided by researchers, but this effect did not persist throughout the day and had no impact on participants' perceptions of their appetites.
› Verified 9 days ago
| Entity Name | Southern California Permanente Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316979834 PECOS PAC ID: 6002729175 Enrollment ID: O20040126000823 |
News Archive
The Prevent COVID U study, which launched in late March 2021 to evaluate SARS-CoV-2 infection and transmission among university students vaccinated with the Moderna COVID-19 Vaccine, has expanded beyond the university setting to enroll young adults ages 18 through 29 years and will now also include people in this age group who choose not to receive a vaccine.
Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that Dr. Geoffrey I. Shapiro of Dana-Farber Cancer Institute, presented preclinical and clinical data on STA-9090, a potent second-generation Hsp90 inhibitor, at IASLC (International Association for the Study of Lung Cancer) 10th Annual Targeted Therapies of the Treatment of Lung Cancer Meeting in Santa Monica, CA.
Isis Pharmaceuticals, Inc. announced the initiation of two Phase 2 studies of ISIS-EIF4ERx in patients with non-small cell lung cancer and prostate cancer. These studies are part of Isis' broad Phase 2 development program designed to evaluate ISIS-EIF4ERx in multiple types of cancer. ISIS-EIF4ERx targets eukaryotic initiation factor-4E (eIF-4E), a traditionally "undruggable" target that is thought to promote tumor growth and metastasis in many cancers.
A new study featured in the Journal of the Academy of Nutrition and Dietetics found that after drinking a small amount of caffeine, participants consumed 10 percent less at a breakfast buffet provided by researchers, but this effect did not persist throughout the day and had no impact on participants' perceptions of their appetites.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Amanda Perri Selwyn Barker, MD 10800 Magnolia Ave, Riverside, CA 92505-3043 Ph: (951) 898-7460 | Dr Amanda Perri Selwyn Barker, MD 10800 Magnolia Ave, Riverside, CA 92505-3043 Ph: (951) 898-7460 |
News Archive
The Prevent COVID U study, which launched in late March 2021 to evaluate SARS-CoV-2 infection and transmission among university students vaccinated with the Moderna COVID-19 Vaccine, has expanded beyond the university setting to enroll young adults ages 18 through 29 years and will now also include people in this age group who choose not to receive a vaccine.
Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that Dr. Geoffrey I. Shapiro of Dana-Farber Cancer Institute, presented preclinical and clinical data on STA-9090, a potent second-generation Hsp90 inhibitor, at IASLC (International Association for the Study of Lung Cancer) 10th Annual Targeted Therapies of the Treatment of Lung Cancer Meeting in Santa Monica, CA.
Isis Pharmaceuticals, Inc. announced the initiation of two Phase 2 studies of ISIS-EIF4ERx in patients with non-small cell lung cancer and prostate cancer. These studies are part of Isis' broad Phase 2 development program designed to evaluate ISIS-EIF4ERx in multiple types of cancer. ISIS-EIF4ERx targets eukaryotic initiation factor-4E (eIF-4E), a traditionally "undruggable" target that is thought to promote tumor growth and metastasis in many cancers.
A new study featured in the Journal of the Academy of Nutrition and Dietetics found that after drinking a small amount of caffeine, participants consumed 10 percent less at a breakfast buffet provided by researchers, but this effect did not persist throughout the day and had no impact on participants' perceptions of their appetites.
› Verified 9 days ago
Luis Escamilla, Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 6177 River Crest Dr Ste A, Riverside, CA 92507 Phone: 951-653-4480 | |
Trisha Gorny, PT Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 6177 River Crest Dr Ste A, Riverside, CA 92507 Phone: 951-653-4480 | |
Dr. Katherine Elizabeth Robb Ramirez, M.D. Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 17735 Log Hill Dr, Riverside, CA 92504 Phone: 951-533-5771 | |
D'hahn House, Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 6177 River Crest Dr, Riverside, CA 92507 Phone: 951-653-4480 | |
Dr. Darren Freeman, D.O. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 3390 University Ave Ste 100, Riverside, CA 92501 Phone: 844-827-2803 | |
Brittney K Tanaka, PT, DPT Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 6177 River Crest Dr, Suite A, Riverside, CA 92507 Phone: 951-653-4480 |